NCT02464657: Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) |
|
|
| Completed | 1/2 | 44 | US | Nivolumab, BMS-936558, Opdivo, Idarubicin, Idamycin, Cytarabine, Ara-C, Cytosar, DepoCyt, Cytosine Arabinosine Hydrochloride, Solu-medrol, Methylprednisolone, Depo-Medrol, Medrol, Dexamethasone, Decadron | M.D. Anderson Cancer Center, Bristol-Myers Squibb | Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome | 05/20 | 05/20 | | |
